Table 2. The loss of ARID1A expression and overall survival in GC.
| Outcome | Cohort (NO.) | Patient (NO.) | HR (95% CI) | P | I2(%) | PH |
|---|---|---|---|---|---|---|
| Overall | 15 | 3183 | 1.60 (1.40, 1.81) | <0.001 | 21.5% | 0.214 |
| Ethnicity | ||||||
| Asian | 12 | 2864 | 1.65 (1.44, 1.89) | <0.001 | 0.0% | 0.915 |
| Non-Asian | 3 | 319 | 1.50 (0.53, 4.20) | 0.444 | 79.9% | 0.007 |
| Location | ||||||
| U ≤ 30% | 4 | 1066 | 1.80 (1.36, 2.38) | <0.001 | 0.0% | 0.589 |
| U > 30% | 2 | 156 | 1.20 (0.40, 3.61) | 0.750 | 71.2% | 0.062 |
| EBV | ||||||
| ≤5% | 3 | 503 | 2.20 (0.93, 5.22) | 0.073 | 79.7% | 0.007 |
| >5% | 2 | 767 | 1.59 (1.18, 2.15) | 0.002 | 0.0% | 0.725 |
| T1,2 | ||||||
| ≤30% | 6 | 1117 | 1.65 (1.21, 2.25) | 0.002 | 42.3% | 0.123 |
| >30% | 6 | 1261 | 1.72 (1.41, 2.10) | <0.001 | 0.0% | 0.935 |
| N0 | ||||||
| ≤30% | 5 | 958 | 1.81 (1.32, 2.50) | <0.001 | 47.5% | 0.107 |
| >30% | 7 | 1492 | 1.55 (1.29, 1.88) | <0.001 | 0.0% | 0.721 |
| Differentiation | ||||||
| G3 ≤ 60% | 7 | 1365 | 1.52 (1.13, 2.06) | 0.006 | 52.5% | 0.049 |
| G3 > 60% | 6 | 1293 | 1.59 (1.32, 1.90) | <0.001 | 0.0% | 0.780 |
| Lauren classification | ||||||
| Diffuse ≤ 40% | 6 | 963 | 1.45 (1.01, 2.08) | 0.042 | 57.5% | 0.038 |
| Diffuse > 40% | 4 | 1075 | 1.79 (1.36, 2.36) | <0.001 | 0.0% | 0.594 |
| MSI | ||||||
| ≤10% | 3 | 1181 | 1.42 (1.10, 1.82) | 0.006 | 0.0% | 0.712 |
| >10% | 6 | 1110 | 1.58 (1.03, 2.41) | 0.036 | 65.4% | 0.013 |
| ARID1A loss | ||||||
| ≤20% | 4 | 955 | 2.32 (1.45, 3.71) | <0.001 | 41.7% | 0.162 |
| >20% | 11 | 2228 | 1.51 (1.31, 1.74) | <0.001 | 0.0% | 0.505 |
| Sample size | ||||||
| ≤200 | 9 | 1178 | 1.61 (1.24, 2.08) | <0.001 | 43.5% | 0.078 |
| >200 | 6 | 2005 | 1.59 (1.33, 1.90) | <0.001 | 0.0% | 0.596 |
U: Upper third part of stomach; EBV: Epstein-Barr virus; MSI: microsatellite instability; HR: hazard ratio; CI: confidence interval; PH: the P value of Cochran Q-test for heterogeneity.